ClinicalTrials.gg
CompletedNCT02870348Updated Mar 31, 2022Results posted

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

A Phase 1/2 interventional study of Alpha-1 MP in Alpha1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
21st of 25
4 · median 30
Started
2016
with 4 others
Phase 1/2
4 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
10 of 25
Grifols Therapeutics LLC

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 21st largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 1/2, and was the 19th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

This is a multi-center, open-label study to evaluate the long-term safety of weekly intravenous (IV) infusions of 60 mg/kg alpha1-PI (human), modified process (Alpha-1 MP) in adult participants with Alpha1 Antitrypsin Deficiency (AATD) in Japan who have completed Study GTI1401 (NCT02870309).

Read the detailed description

This is a multi-center, open-label study to evaluate the long-term safety of weekly IV infusions of 60 mg/kg Alpha-1 MP in adult participants with AATD in Japan who have completed Study GTI1401. Study GTI1401 is being conducted to evaluate the safety and pharmacokinetics (PK) of Alpha-1 MP in participants with AATD in Japan. In the current study, GTI1401-OLE, participants will be administered 60 mg/kg Alpha-1 MP by weekly IV infusion for approximately 1 year (can be renewed annually with the consent of the participants unless the sponsor informs of discontinuation of this OLE trial) to assess the long-term safety of Alpha-1 MP in participants with AATD. This study will be conducted at up to 5 centers in Japan.

At the Week 9 Visit of Study GTI1401, after giving consent, on the same day, participants will be assessed for eligibility at Screening/Extension (Ext) Week 1 Visit for this extension study, Study GTI1401-OLE. If eligible, participants will be administered weekly IV infusions of 60 mg/kg Alpha-1 MP for approximately 1 year or longer. The Week 9 Visit of GTI1401 will be the End of Study Visit for the participants who are enrolled in Study GTI1401-OLE.

Participants in Study GTI1401-OLE will have the option to remain in Study GTI1401-OLE and continue to receive weekly IV infusions of 60 mg/kg Alpha-1 MP for another year or longer. If participants plan to conclude their participation in the study (GTI1401-OLE) early (before Ext. Week 52), participants will be asked to complete the End of Study Follow-Up Assessments, which will be scheduled 4 weeks after the last infusion.

03

Conditions studied

  • Alpha1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who complete participation in Study GTI1401 (i.e., have completed the study through the Week 9 Visit).
  • Subjects who will and are able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Subjects with newly diagnosed severe concomitant disease including, but not limited to, congestive heart failure and liver cirrhosis.
  • Subjects with newly diagnosed malignant tumor (including malignant melanoma; however, other forms of skin cancer are allowed).
  • Female subjects who are pregnant, breastfeeding or, if of , unwilling to practice a highly effective method of (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or abstinence) throughout the study or male subjects who have a partner who is of child-bearing potential and is unwilling to practice a highly effective method of contraception throughout the study.
  • Subjects with clinical signs and symptoms of active hepatitis A virus (HAV), virus (HBV), virus (HCV), or (HIV) viral infection at the Week 9 Visit of Study GTI1401 and viral infection is further confirmed by testing.
  • Subjects with current evidence of smoking or has a positive urine cotinine test at the Week 9 Visit in Study GTI1401 that is due to smoking.
  • Subjects who currently participate in a study of another product (other than Alpha-1 MP).
  • Subjects who have difficulty in adhering to the protocol or its procedures, in the opinion of the investigator.
  • Subjects who have medical conditions that may confound the results of this clinical trial or may endanger these subjects during their participation in this clinical trial in the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Alpha-1 MP

    Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.

    Biological: Alpha-1 MP

Interventions

  • BiologicalAlpha-1 MP

    Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.

    Also known as: Prolastin-C

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  2. Number of Participants With Adverse Drug Reaction (ADRs)

    ADRs were defined as all noxious and unintended responses to a medicinal product or study treatment related to any dose. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  3. Number of Participants With Serious Adverse Events (SAEs)

    An AE was considered serious in any of the following outcomes or deemed significant for any other reason: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  4. Number of Participants With Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration. An AE was considered serious in any of the following outcomes or deemed significant for any other reason: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  5. Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

    COPD exacerbation was defined as an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  6. Number of Participants With Clinically Significant Findings in Vital Signs

    Vital signs included analysis of heart rate, blood pressure, respiratory rate, and temperature. Clinically significant findings in vital signs were based on investigator's discretion.

    Time frame: From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)

  7. Number of Participants With Clinically Significant Findings in Clinical Laboratory Parameters

    Clinical laboratory parameters included analysis of hematology, blood chemistry, and urinalysis. Clinically significant findings in clinical laboratory parameters were based on investigator's discretion.

    Time frame: Extension (Ext) Weeks 26, 52, 78, 104, 130, 156,182, 208 (prior to study drug administration) until end of study (Up to 228 weeks)

  8. Number of Participants With Clinically Significant Findings in Pulmonary Function Tests (PFTs)

    Pulmonary function tests were measured by spirometry. It included Forced Expired Volume in 1 second (FEV1), Forced Vital Capacity (FVC), which were performed according to American Thoracic Society/ European Respiratory Society (ATS/ERS) guidelines. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. PFTs were performed before infusion both pre- and post-bronchodilator administration. The post-bronchodilator PFT was performed 15 to 30 minutes after bronchodilator administration. The same bronchodilator was used throughout the study. Clinically significant findings in pulmonary function tests were based on investigator's discretion.

    Time frame: Extension (Ext) Weeks 26, 52, 78, 104, 130, 156,182, 208 (prior to study drug administration) until end of study (Up to 228 weeks)

  9. Trough Levels of Alpha1- Proteinase Inhibitor

    Alpha1-PI level was measured by nephelometry.

    Time frame: Extension (Ext) Weeks 12, 24, 36, 48, 64, 76, 88, 100, 116, 128, 140, 152, 168, 180, 192, 204 (prior to study drug administration) until end of study (Up to 228 weeks)

07

Results

Posted Mar 21, 2022

Participant flow

The study was conducted at 3 investigative sites in Japan from 29 July 2016 to 16 February 2021.

Participant flow — Overall Study
MilestoneAlpha-1 MP
Started4
Completed0
Not completed4
Withdrew: Participants were discontinued and assessed for entry into post-marketing study (gti1401-exp)4

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAlpha-1 MP
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)4
PrimaryNumber of Participants With Adverse Drug Reaction (ADRs)

ADRs were defined as all noxious and unintended responses to a medicinal product or study treatment related to any dose. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Drug Reaction (ADRs)
ParticipantsAlpha-1 MP
Number of Participants With Adverse Drug Reaction (ADRs)2
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An AE was considered serious in any of the following outcomes or deemed significant for any other reason: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsAlpha-1 MP
Number of Participants With Serious Adverse Events (SAEs)2
PrimaryNumber of Participants With Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product or study treatment and which did not necessarily have a causal relationship with this administration. An AE was considered serious in any of the following outcomes or deemed significant for any other reason: death; life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)
ParticipantsAlpha-1 MP
Number of Participants With Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)0
PrimaryNumber of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

COPD exacerbation was defined as an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
ParticipantsAlpha-1 MP
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations0
PrimaryNumber of Participants With Clinically Significant Findings in Vital Signs

Vital signs included analysis of heart rate, blood pressure, respiratory rate, and temperature. Clinically significant findings in vital signs were based on investigator's discretion.

Time frame:
From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Vital Signs
ParticipantsAlpha-1 MP
Number of Participants With Clinically Significant Findings in Vital Signs0
PrimaryNumber of Participants With Clinically Significant Findings in Clinical Laboratory Parameters

Clinical laboratory parameters included analysis of hematology, blood chemistry, and urinalysis. Clinically significant findings in clinical laboratory parameters were based on investigator's discretion.

Time frame:
Extension (Ext) Weeks 26, 52, 78, 104, 130, 156,182, 208 (prior to study drug administration) until end of study (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Clinical Laboratory Parameters
ParticipantsAlpha-1 MP
Number of Participants With Clinically Significant Findings in Clinical Laboratory Parameters0
PrimaryNumber of Participants With Clinically Significant Findings in Pulmonary Function Tests (PFTs)

Pulmonary function tests were measured by spirometry. It included Forced Expired Volume in 1 second (FEV1), Forced Vital Capacity (FVC), which were performed according to American Thoracic Society/ European Respiratory Society (ATS/ERS) guidelines. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. PFTs were performed before infusion both pre- and post-bronchodilator administration. The post-bronchodilator PFT was performed 15 to 30 minutes after bronchodilator administration. The same bronchodilator was used throughout the study. Clinically significant findings in pulmonary function tests were based on investigator's discretion.

Time frame:
Extension (Ext) Weeks 26, 52, 78, 104, 130, 156,182, 208 (prior to study drug administration) until end of study (Up to 228 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Pulmonary Function Tests (PFTs)
ParticipantsAlpha-1 MP
Number of Participants With Clinically Significant Findings in Pulmonary Function Tests (PFTs)0
PrimaryTrough Levels of Alpha1- Proteinase Inhibitor

Alpha1-PI level was measured by nephelometry.

Time frame:
Extension (Ext) Weeks 12, 24, 36, 48, 64, 76, 88, 100, 116, 128, 140, 152, 168, 180, 192, 204 (prior to study drug administration) until end of study (Up to 228 weeks)
Reported as:
Mean · milligram/deciliter (mg/dL)
Trough Levels of Alpha1- Proteinase Inhibitor
milligram/deciliter (mg/dL)Alpha-1 MP
Trough Levels of Alpha1- Proteinase Inhibitor55.734 ± 4.9928

Adverse events

Collected over From start of study drug administration through 30 days after last study drug infusion (Up to 228 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1 MP0/4 (0%)2/4 (50%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventAlpha-1 MP
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders1/4
PneumoniaInfections and infestations1/4
CellulitisInfections and infestations1/4
Large intestine polypGastrointestinal disorders1/4
PneumothoraxRespiratory, thoracic and mediastinal disorders1/4
Most frequent other events
Showing 10 of 31
Most frequent other events
EventAlpha-1 MP
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders4/4
Back painMusculoskeletal and connective tissue disorders3/4
Abdominal discomfortGastrointestinal disorders2/4
Hepatic function abnormalHepatobiliary disorders2/4
NasopharyngitisInfections and infestations2/4
Arthropod stingInjury, poisoning and procedural complications2/4
ArthralgiaMusculoskeletal and connective tissue disorders2/4
ArrhythmiaCardiac disorders1/4
PalpitationsCardiac disorders1/4
Conjunctival haemorrhageEye disorders1/4

Baseline characteristics

Safety Population included all participants who received any amount of Alpha-1 MP.

Age, Continuous
Age, Continuous(years)Alpha-1 MP
Mean60.8 ± 5.56
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1 MP
Female1
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpha-1 MP
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Hiroskai University Hospital
    Aomori, 036-8563, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
09

References and documents

Publications

  • Seyama K, Suzuki M, Tasaka S, Nukiwa T, Sato T, Konno S, Sorrells S, Chen J, Aragones ME, Minamino H. Long-term safety of Prolastin(R)-C, an alpha1-proteinase inhibitor, in Japanese patients with alpha1-antitrypsin deficiency. Respir Investig. 2022 Nov;60(6):831-839. doi: 10.1016/j.resinv.2022.07.001. Epub 2022 Aug 12. PubMed 35970714 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Feb 2021, 54 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 17, 2016
StartActual
Jul 29, 2016
Primary completionActual
Feb 16, 2021
CompletionActual
Feb 16, 2021
Results first posted
Mar 21, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02870348
Collaborators
Grifols Japan K.K.
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Jul 29, 2016
Primary completion
Feb 16, 2021
Completion
Feb 16, 2021
Results posted
Mar 21, 2022
Last update
Mar 31, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion